DGX
US EQUITY
Health Care
Health Care Services
CIK: 1022079
Quest Diagnostics (DGX) Quant Factor Diagnostic & Fair Value Model
Quest Diagnostics (Ticker: DGX) is listed in the Health Care sector (Health Care Services). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$241.89
-0.57%
Latest Close (2026-10-23)
Market Cap: $227.64M
P/E Ratio: 21.3
Momentum Strength
3M / 12M
+4.33%
1M: +2.24%
12M: +33.52%
Quality (ROE)
Point-in-Time
+8.45%
Trailing Return on Equity
Technical Trend
RSI 14
63.6
SMA50: $237.60
SMA200: $210.44
Valuation Multiplier
Trailing
21.3
Moderate Valuation Corridor (15x - 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Moderate Valuation Corridor (15x - 30x P/E)
DGX trades within a typical sector multiple band (21.3x P/E), broadly aligned with trailing earnings.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 8/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 1022079 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-07-23 | $3.04B | $320.00M | $875.00M | $2.84 |
| 10-Q | 2025-12-31 | 2026-07-23 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-07-23 | $2.76B | $282.00M | $858.00M | $2.47 |
| 10-Q | 2026-03-31 | 2026-04-22 | $2.90B | $252.00M | $278.00M | $2.24 |
| 10-Q | 2025-03-31 | 2026-04-22 | $2.65B | $220.00M | $314.00M | $1.94 |
| 10-K | 2025-12-31 | 2026-02-26 | $11.04B | $992.00M | $1.89B | $8.75 |
| 10-K | 2024-12-31 | 2026-02-26 | $9.87B | $871.00M | $1.33B | $7.69 |
| 10-K | 2023-12-31 | 2026-02-26 | $9.25B | $854.00M | $1.27B | $7.49 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Quest Diagnostics (DGX) valuation multiples, momentum factors, and point-in-time filing conventions.
How should DGX's current valuation multiple be interpreted? ↓
DGX trades at a trailing P/E of 21.3x within the Health Care sector (moderate valuation corridor (15x - 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are DGX's key momentum and technical factor indicators? ↓
As of the latest close, DGX shows a 1-month return of +2.24%, 3-month return of +4.33%, and 12-month return of +33.52%, with a 14-day RSI of 63.6. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for DGX? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can DGX be incorporated into systematic factor models? ↓
DGX can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.